On Friday, Shares of Southwest Airlines Co (NYSE:LUV), lost -1.65% to $40.56. 8.19 million shares of the company were exchanged.
The stock is down -3.66% in this year through last close, and the beta ratio has a value of 0.65. The stock, as of recent close, has shown weekly upbeat performance of 1.55% which was maintained at 2.71% in 1-month period.
Southwest Airlines Co. (LUV) invites you to listen to a live webcast of its third quarter 2015 financial results. Details are as follows:
When: Thursday, October 22, 2015 at 12:30 PM Eastern Time
Who: Gary Kelly, Chairman of the Board, President and Chief Executive Officer
Tammy Romo, Executive Vice President and Chief Financial Officer
Southwest Airlines Co. operates passenger airlines that provide planned air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft.
Shares of eBay Inc (NASDAQ:EBAY), surged 0.16% to $24.55, during its last trading session.
The share price of this stock traded recently in a range of $24.40 to $24.72. The company now has a market value of $29.86 billion.
For this company, beta value at 0.86 represents it is more volatile to the shift in the market. If we take a look on its volatility, 2.41% was seen in a week and for the month it was 2.61%.
eBay Inc. operates as a technology company that enables commerce and payments on behalf of users, merchants, retailers, and brands of various sizes in the United States and internationally.
Finally, Shares of Opko Health Inc. (NYSE:OPK), ended its last trade with 1.19% gain, and closed at $9.39.
OPKO Health, Inc. (OPK) declared a partnership among its partner, Bio Reference Laboratories, Inc., the Department of Pathology, Microbiology, and Immunology and the Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC) to leverage large scale genomics testing for optimal cancer care. Each of the organizations has committed to providing its complementary expertise with the aim of introducing genomic testing that is cost effective and enhances patient accessibility to the newest cancer therapies.
VUMC is recognized nationally for clinical and administration excellence by such organizations as U.S. News and World Report, Leapfrog, and Truven (formerly Thomson Reuters) Top 100 Hospitals. VICC, a NCI-designated Comprehensive Cancer Center, is a recognized leader in precision medicine with active clinical trials involving biomarker assessment. BioReference Laboratories, through its business units, GenPath Oncology and GeneDx, has extensive experience in next-generation sequencing (NGS) in oncology.
The first initiative in this multi-year partnership is a 300+ gene NGS panel for solid tumors and hematologic malignancies that will be accessible in early 2016 for clinical care. The panel design was jointly developed by VICC/VUMC pathologists, oncologists, and cancer researchers and scientists at BioReference Laboratories. This NGS assay will target single nucleotide variants, insertions and deletions, copy number variants, and gene fusions specifically in genomic areas that are druggable.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
